Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody

被引：8

作者：

Dekhtiarenko, Iryna ^{[1
]}

Lelios, Iva ^{[2
]}

Jacob, Wolfgang ^{[3
]}

Schneider, Meike ^{[2
]}

Weisser, Martin ^{[3
]}

Carlo-Stella, Carmelo ^{[4
,5
]}

Manier, Salomon ^{[6
,7
]}

Harrison, Simon J. ^{[8
]}

Popat, Rakesh ^{[9
]}

Riley, Anna Caroline Hasselbalch ^{[10
]}

Broeke, Ann-Marie E. ^{[3
]}

机构：

[1] Roche Innovat Ctr Zurich, Zurich, Switzerland

[2] Roche Innovat Ctr Basel, Basel, Switzerland

[3] Roche Innovat Ctr Munich, Penzberg, Germany

[4] Humanitas Univ, Milan, Italy

[5] IRCCS Humanitas Res Hosp, Milan, Italy

[6] CHU Lille, Lille, France

[7] Univ Melbourne, Peter MacCallum Canc Ctr, Sir Peter MacCallum Dept Oncol, Melbourne, Australia

[8] Royal Melbourne Hosp, Melbourne, Australia

[9] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England

[10] Rigshosp, Dept Hematol, Copenhagen, Denmark

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177669

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 24 条

[1] Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).
Janardan, Abhishek
Lindsay, Hammons
Szabo, Aniko
Bhatlapenumarthi, Vineel
Annyapu, Evanka
Dhakal, Binod
Narra, Ravi Kishore
Al Hadidi, Samer
Radhakrishnan, Sabarinath Venniyil
Bhutani, Divaya
Thanendrarajan, Sharmilan
Siegfried, Janz
Zangari, Maurizio
Lentzsch, Suzanne
van Rhee, Frits
D'Souza, Anita
Chakraborty, Rajshekhar
Schinke, Carolina D.
Mohan, Meera
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses
Harrison, Simon
Riley, Caroline Hasselbalch
Manier, Salomon
Yoon, Sung-Soo
Pinto, Antonio
Cazaubiel, Titouan
Guidetti, Anna
Popat, Rakesh
Touzeau, Cyrille
Ocio, Enrique
Offner, Fritz
Rodriguez-Otero, Paula
Rizzello, Ilaria
Mateos, Maria-Victoria
Broeske, Ann-Marie
Dekhtiarenko, Iryna
Dimier, Natalie
Eckmann, Jan
Helms, Hans-Joachin
Jacob, Wolfgang
Schneider, Meike
Sleiman, Nassim
Weisser, Martin
Carlo-Stella, Carmelo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S3 - S4
[3] Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
Schinke, Carolina D.
Touzeau, Cyrille
Minnema, Monique C.
van de Donk, Niels W. C. J.
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Rasche, Leo
Ye, Jing Christine
Vishwamitra, Deeksha
Ma, Xuewen
Qin, Xiang
Campagna, Michela
Masterson, Tara J.
Hilder, Brandi
Tolbert, Jaszianne A.
Renaud, Thomas
Goldberg, Jenna
Heuck, Christoph
Chari, Ajai
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] Pivotal Phase 2 MonumenTAL-1 results of Talquetamab (tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), for Relapsed/Refractory Multiple Myeloma (RRMM)
Schinke, C.
Touzeau, C.
Minnema, M. C.
van de Donk, N. W.
Rodriguez-Otero, P.
Mateos, M. -V.
Rasche, L.
Ye, J. C.
Vishwamitra, D.
Ma, X.
Qin, X.
Campagna, M.
Masterson, T.
Hilder, B.
Tolbert, J.
Renaud, T.
Goldberg, J.
Heuck, C.
Chari, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 82 - 83
[5] Talquetamab, a GPRC5DXCD3 Bispecific Antibody, for Treatment of Relapsed/Refractory Multiple Myeloma in Patients With Prior Exposure to BCMA Targeted Therapies - a "Real World" Study
Shkury, Eden
Hellou, Tamer
Nevo, Lee
Avigdor, Abraham
Magen, Hila
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S88 - S89
[6] Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
Dekhtiarenko, Iryna
Lelios, Iva
Attig, Jan
Sleiman, Nassim
Lazzaro, Domenico
Schindler, Emilie
Eckmann, Jan
Umana, Pablo
Jacob, Wolfgang
Schneider, Meike
Carlo-Stella, Carmelo
Mazza, Rita
Manier, Salomon
Facon, Thierry
Yoon, Sung-Soo
Koh, Youngil
Harrison, Simon J.
Er, Jeremy
Pinto, Antonio
Volzone, Francesco
Perrone, Giulia
Corradini, Paolo
Cazaubiel, Titouan
Hulin, Cyrille
Touzeau, Cyrille
Moreau, Philippe
Ocio, Enrique M.
Gaisan, Carmen Maria Montes
Popat, Rakesh
Leong, Sarah
Offner, Fritz
Otero, Paula Rodriguez
Alfonso-Pierola, Ana
Hutchings, Martin
Riley, Caroline Hasselbalch
Broske, Ann-Marie E.
BLOOD, 2022, 140 : 10137 - 10139
[7] Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Rasche, Leo
Schinke, Carolina
Touzeau, Cyrille
Minnema, Monique C.
van de Donk, Niels W. C. J.
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Ye, Jing Christine
Vishwamitra, Deeksha
Singh, Indrajeet
Qin, Xiang
Campagna, Michela
Masterson, Tara
Hilder, Brandi W.
Tolbert, Jaszianne
Renaud, Thomas
Heuck, Christoph
Kane, Colleen
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S561 - S562
[8] Efficacy and Safety of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study
Ito, Shigeki
Kuroda, Yoshiaki
Sunami, Kazutaka
Matsue, Kosei
Imada, Kazunori
Tamura, Hideto
Takamoto, Mikihiro
Yamazaki, Hiroshi
Fujikawa, Ei
Pei, Lixia
Masterson, Tara J.
Campagna, Michela
Lau, Bonnie W.
Takamatsu, Yasushi
BLOOD, 2024, 144 : 7011 - 7012
[9] Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Ye, Jing Christine
Schinke, Carolina
Touzeau, Cyrille
Minnema, Monique
van de Donk, Niels
Rodriguez-Otero, Paula
Mateos Manteca, Maria-Victoria
Rasche, Leo
Vishwamitra, Deeksha
Singh, Indrajeet
Qin, Xiang
Campagna, Michela
Hilder, Brandi
Tolbert, Jaszianne
Renaud, Thomas
Heuck, Christoph
Kane, Colleen
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S99 - S99
[10] Prophylactic Interventions for Oral Toxicities With the GPRC5DxCD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase 2, Randomized Study (TALISMAN)
Popat, Rakesh
Laheij, Alexa
van de Donk, Niels
Doty, Richard
Omel, Jim
Lipe, Brea
Rasche, Leo
Chari, Ajai
Kato, Kelly
Tian, Ken
Vishwamitra, Deeksha
Speier, Jacqueline
Durand, Mathilde
Northup, Margaret
Saber, Ibrahim
Prada, William
Gray, Kathleen
Aguilar, Gloria
Sanchez, Larysa
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S79 - S80

← 1 2 3 →